Strategies to Improve the Affordability of Insulin in the USA

Jing Luo,Aaron S Kesselheim,Jeremy Greene,Kasia J Lipska

DOI: https://doi.org/10.1016/s2213-8587(17)30041-4

2017-01-01

Abstract:Global challenges regarding access to insulin have been documented in low-income and middle-income countries, 1 Beran D Ewen M Laing R Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016; 4: 275-285 Summary Full Text Full Text PDF PubMed Scopus (107) Google Scholar but high-income countries are not exempt from these problems. In the USA, where the entire insulin supply comes from only three manufacturers, prices have risen sharply, complicating access to this essential medicine (table). In 2015, Medicare Part D—the outpatient prescription drug benefit associated with the government insurance programme for patients older than 65 years—spent more than US$4·3 billion for just one long-acting insulin analogue, glargine. 2 Centers for Medicaid and Medicare ServicesCMS Drug Spending dashboards. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/ Google Scholar Expenditures on glargine were the second largest of all Part D drugs that year, just after those for ledipasvir–sofosbuvir, an antiviral agent used to treat hepatitis C. That same year, Medicaid—the federal-funded and state-funded health insurance programme for people with a low income—spent more than $1·4 billion on glargine. TableUS spending during 2015 for insulin glargine and lispro, excluding rebates Glargine* Lantus and Lantus Solostar (Sanofi-Aventis, Bridgewater, NJ, USA). (Medicare Part D) Glargine* Lantus and Lantus Solostar (Sanofi-Aventis, Bridgewater, NJ, USA). (Medicaid) Lispro† Humalog (Eli Lilly and Company, Indianapolis, IN, USA). (Medicaid) Total spending in 2015, US$ $4 359 504 167 $1 435 574 715 $355 593 188 Number of beneficiaries 1 673 911 NA NA Prescription count NA 3 651 839 941 420 Spending per Medicare beneficiary $2604 NA NA Spending per Medicaid prescription NA $393 $378 Weighted annual % change (vs 2014) 15% 15% 21% Data are from Centers for Medicaid and Medicare Services Drug Spending Dashboards. 2 Centers for Medicaid and Medicare ServicesCMS Drug Spending dashboards. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/ Google Scholar NA=not applicable. * Lantus and Lantus Solostar (Sanofi-Aventis, Bridgewater, NJ, USA). † Humalog (Eli Lilly and Company, Indianapolis, IN, USA). Open table in a new tab Data are from Centers for Medicaid and Medicare Services Drug Spending Dashboards. 2 Centers for Medicaid and Medicare ServicesCMS Drug Spending dashboards. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/ Google Scholar NA=not applicable. The bare essentials: ensuring affordable access to insulinThe cost and availability of insulin is a growing concern and an issue of worldwide importance. The skyrocketing list prices of insulin—along with those of certain other drugs and medical products—in the USA became a major political issue last year. More recently, in January, 2017, a lawsuit was filed in a federal court in Massachusetts alleging that the three pharmaceutical companies that control the insulin market in the USA and worldwide (Eli Lilly, Novo Nordisk, and Sanofi) have been raising list prices to exploit the drug-pricing system to benefit themselves and pharmacy benefit managers, which are the go-betweens that receive a cut of rebates paid to insurers. Full-Text PDF Insulin affordabilityIn their excellent Comment on insulin pricing, Jing Luo and colleagues1 implied that Frederick Banting's name was on the first insulin processing patent along with James B Collip and Charles Best. But as Michael Bliss2 wrote in his 1984 biography, Banting felt “…that as a physician who had taken the Hippocratic oath he could not be party to any patenting of a discovery. The first application, therefore, was in the name of Best and Collip.” This is confirmed in the assignment of patent rights (figure). Full-Text PDF